Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record.

Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer

Vinageras, Elia Neninger, de la Torre, Ana, Rodríguez, Marta Osorio, Ferrer, Mauricio Catalá, Bravo, Idania, del Pino, Mario Mendoza, Abreu, Daniel Abreu, Brooks, Soraida Acosta, Rives, Rolando, del Castillo Carrillo, Concepción, Dueñas, Marta González, Viada, Carmen, Verdecia, Beatriz García, Ramos, Tania Crombet, Marinello, Gisela González, Dávila, Agustín Lage · 2008 · Journal of Clinical Oncology

Abstract

Purpose: We show the result of a randomized phase II clinical trial with an epidermal growth factor (EGF)-based cancer vaccine in advanced non–small-cell lung cancer (NSCLC) patients, evaluating immunogenicity, safety, and effect on survival. Patients and Methods: Eighty patients with stage IIIB/IV NSCLC after finishing first-line chemotherapy were randomly assigned to receive best supportive care or EGF vaccinations. Results: Vaccination was safe. Adverse events were observed in less than 25% of cases and were grade 1 or 2 according to National Cancer Institute Common Toxicity Criteria. Good anti-EGF antibody response (GAR) was obtained in 51.3% of vaccinated patients and in none of the control group. Serum EGF concentration showed a major decrease in 64.3% of vaccinated patients. GAR patients survived significantly more than those with poor antibody response (PAR). Also, patients whose serum EGF dropped below 168 pg/mL survived significantly more than the rest. There was a trend to an increased survival for vaccinated patients compared with controls. The survival advantage for vaccinated patients compared with controls was statistically significant in the subgroup of patients with age younger than 60 years. Conclusion: Vaccination with EGF was safe and provoked an increase in anti-EGF antibody titers and a decrease in serum EGF. There was a direct correlation between antibody response and survival. There was a direct correlation between decrease in serum EGF and survival. In patients younger than 60 years, vaccination was associated with increased survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.11.5980

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 199

Metadata

Authors
Vinageras, E. N., de la Torre, A., Rodríguez, M. O., Ferrer, M. C., Bravo, I., del Pino, M. M., Abreu, D. A., Brooks, S. A., Rives, R., del Castillo Carrillo, C., Dueñas, M. G., Viada, C., Verdecia, B. G., Ramos, T. C., Marinello, G. G., & Dávila, A. L.
Venue
Journal of Clinical Oncology
Published
2008-03-20
Volume
26
Issue
9
Pages
1452-1458
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2147996829
Cited by
199
References
0
FWCI
4.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2007.11.5980
The paper
Vinageras, E. N., de la Torre, A., Rodríguez, M. O., Ferrer, M. C., Bravo, I., del Pino, M. M., Abreu, D. A., Brooks, S. A., Rives, R., del Castillo Carrillo, C., Dueñas, M. G., Viada, C., Verdecia, B. G., Ramos, T. C., Marinello, G. G., & Dávila, A. L. (2008). Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.11.5980

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.